Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
308710
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
NDF-RT |
N0000184163
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
182503
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
136800
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
WHO-VATC |
QL04AA04
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
64491
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
301810
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
226006
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
838821
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
NCI_THESAURUS |
C2701
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
||
|
WHO-ATC |
L04AA04
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C80833
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
SUB128808
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
DB00098
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
N0000178327
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Lymphocyte Function Alteration [PE] | ||
|
308067-60-9
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
GENERIC (FAMILY) | |||
|
D7RD81HE4W
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
N0000009689
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Increased T Lymphocyte Destruction [PE] | ||
|
N0000007920
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Immunoglobulins [Chemical/Ingredient] | ||
|
N0000020023
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | Antibody-Surface Protein Interactions [MoA] | ||
|
D7RD81HE4W
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY | |||
|
C512542
Created by
admin on Sat Dec 16 05:21:29 UTC 2023 , Edited by admin on Sat Dec 16 05:21:29 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
